Glenmark launches triple FDC of Teneligliptin with Pioglitazone, Metformin in India

18 Oct 2023 , 10:51 AM

In India, the first triple fixed-dose formulation of teneligliptin, pioglitazone, and metformin was made available by Glenmark Pharmaceuticals Limited (Glenmark). Teneligliptin is a widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor).

This FDC has been launched under the brand name Zita-PioMet and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation. This offers patients with type 2 diabetes the convenience of once-daily dosing to improve their glycemic control and achieve the targeted HbA1c within 24 weeks.

Glenmark Pharmaceuticals Ltd. Commenting on the launch, Alok Malik,  Head of Formulations India, said: ‘Type 2 diabetes patients in India often suffer from beta-cell dysfunction and insulin resistance. An innovative, effective and affordable drug helps improve glycemic control in adult patients with high HbA1c.’ 

According to IQVIA sales data for the 12 months ending November 2022, the oral diabetes market size in India is estimated to be Rs 11,877 crore, growing at 6.3% YoY (MAT November 2021). According to the International Diabetes Federation (IDF), the prevalence of diabetes in India is expected to increase to 125 million by 2045, of which 77% would have uncontrolled diabetes.

For feedback and suggestions, write to us at [e-mail]